FIELD: medicine.
SUBSTANCE: invention refers to medicine and biotechnology area and concerns antibody polypeptides ensuring monovalent binding of CD40L. Substance of the invention involves antibody polypeptides ensuring monovalent binding of CD40L and can inhibit activity of CD40L while allowing avoiding potential undesirable results of application of antibodies able for bivalent and multivalent binding of CD40L. In one perspective, polypeptide of monovalent anti-Cd40L antibody consists of, or contains single variable immunoglobulin domain which specifically binds and inhibits activity of CD40L, preferentially to a wide extent not stimulating activity of CD40 and/or CD40L. In the other perspective, polypeptide of monovalent anti-Cd40L antibody represents human antibody polypeptide. The present invention also involves methods of CD40/CD40L interaction inhibition in a human organism and therapies of diseases or disorders involving CD40/CD40L interactions, including introduction to a patient of polypeptide of monovalent anti-CD40L antibody.
EFFECT: advantage of the invention consists in higher specificity.
73 cl, 9 ex, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
| NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
| ANTIBODIES TO MST1R AND THEIR APPLICATION | 2010 |
|
RU2534890C2 |
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| ANTIBODIES TO GLUCAGON RECEPTOR AND THEREOF APPLICATION | 2009 |
|
RU2562110C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| IMPROVED NANO-BODIES AGAINST HUMAN SERUM ALBUMIN | 2012 |
|
RU2634381C2 |
| ANTIBODIES TARGETING A RECEPTOR BOUND TO G-PROTEINS, AND METHODS FOR USE THEREOF | 2015 |
|
RU2725819C2 |
